牛牛AI助理已提取核心訊息
Bristol-Myers Squibb Company (BMS), through its subsidiary Rudolph Merger Sub Inc., has announced a tender offer to acquire all outstanding shares of RayzeBio, Inc. for $62.50 per share in cash. The offer is part of a definitive merger agreement aimed at acquiring the entire equity interest in RayzeBio, making it a wholly owned subsidiary of BMS. The tender offer is subject to customary conditions, including the receipt of a majority of RayzeBio's shares and regulatory approvals. The offer, dated January 25, 2024, is not contingent on financing. BMS plans to finance the acquisition through cash on hand, debt issuance, or borrowing. The merger is expected to follow promptly after the tender offer's completion, subject to the satisfaction of remaining conditions. RayzeBio specializes in radiopharmaceutical therapeutics, with its lead program in Phase 3 clinical trials. The acquisition aligns with BMS's strategic focus on innovative medicines for serious diseases.
Bristol-Myers Squibb Company (BMS), through its subsidiary Rudolph Merger Sub Inc., has announced a tender offer to acquire all outstanding shares of RayzeBio, Inc. for $62.50 per share in cash. The offer is part of a definitive merger agreement aimed at acquiring the entire equity interest in RayzeBio, making it a wholly owned subsidiary of BMS. The tender offer is subject to customary conditions, including the receipt of a majority of RayzeBio's shares and regulatory approvals. The offer, dated January 25, 2024, is not contingent on financing. BMS plans to finance the acquisition through cash on hand, debt issuance, or borrowing. The merger is expected to follow promptly after the tender offer's completion, subject to the satisfaction of remaining conditions. RayzeBio specializes in radiopharmaceutical therapeutics, with its lead program in Phase 3 clinical trials. The acquisition aligns with BMS's strategic focus on innovative medicines for serious diseases.
百時美施貴寶公司（BMS）通過其子公司Rudolph Merger Sub Inc. 宣佈要約收購RayzeBio, Inc.的所有已發行股份，以每股62.50美元的現金收購RayzeBio, Inc.的所有已發行股份。該要約是最終合併協議的一部分，該協議旨在收購RayzeBio的全部股權，使其成爲BMS的全資子公司。要約要約受慣例條件的約束，包括獲得RayzeBio的大部分股票和監管部門的批准。該報價的日期爲2024年1月25日，不以融資爲條件。BMS計劃通過手頭現金、債務發行或借款爲收購融資。合併預計將在要約完成後立即進行，但須滿足其餘條件。RayzeBio專門研究放射性藥物療法，其主導項目是3期臨床試驗。此次收購符合BMS對治療嚴重疾病的創新藥物的戰略重視。
百時美施貴寶公司（BMS）通過其子公司Rudolph Merger Sub Inc. 宣佈要約收購RayzeBio, Inc.的所有已發行股份，以每股62.50美元的現金收購RayzeBio, Inc.的所有已發行股份。該要約是最終合併協議的一部分，該協議旨在收購RayzeBio的全部股權，使其成爲BMS的全資子公司。要約要約受慣例條件的約束，包括獲得RayzeBio的大部分股票和監管部門的批准。該報價的日期爲2024年1月25日，不以融資爲條件。BMS計劃通過手頭現金、債務發行或借款爲收購融資。合併預計將在要約完成後立即進行，但須滿足其餘條件。RayzeBio專門研究放射性藥物療法，其主導項目是3期臨床試驗。此次收購符合BMS對治療嚴重疾病的創新藥物的戰略重視。
有用
沒用